Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes

Abstract

Aim: Nonalcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is projected to become the leading indication for liver transplantation. Previous studies indicate that tumor growth rates (TGR) may predict survival and were helpful in determining HCC surveillance intervals. Therefore, we aimed to determine its usefulness in predicting clinical outcomes and treatments.

Methods: We conducted a retrospective study of hepatitis B, C and NAFLD-HCC cases. TGR was measured using 2-consecutive pre-treatment contrast-enhanced imaging studies ≥ 25 days apart. A multivariate regression model was used to determine predictors of TGR. In addition, the Cox regression model was used to evaluate the relationship between TGR and overall survival.

Results: From 2000-2019, the study cohort comprised 38, 60, and 47 HBV, HCV, and NAFLD patients, respectively, with TGRs. NAFLD-HCC tumor size was inversely correlated to the extent of liver disease as measured by Child-Pugh score (7.2 cm in non-cirrhosis; 3.7 cm, 2.6 cm, and 2.1 cm in Child A, B, and C, respectively; P < 0.001). After adjusting for baseline characteristics, the TGR per month was fastest in HBV (9.4%, 95%CI: 6.3%-12.5%) compared to HCV (4.9%, 95%CI: 2.8%-7%) and NAFLD patients (3.6%, 95%CI: 1.6%-6.7%). Predictors of TGR included elevated AFP, low albumin, and smaller tumor size. Fast TGR in viral etiologies had higher mortality [adj. hazard ratio (HR) = 2.6, 95%CI: 1.2-5.7, P = 0.02] than slow TGRs, independent of treatments. Fast TGR in NAFLD had a trend towards higher mortality (HR = 3.6, 95%CI: 0.95-13.3, P = 0.059).

Conclusion: NAFLD-HCC patients have more indolent growths than viral-related HCC TGRs. The addition of TGR as a biomarker may assist in stratifying treatment options.

Keywords

Nonalcoholic fatty liver disease / hepatocellular carcinoma / tumor growth rates / biomarker

References

[1] Schwartz M.A biomathematical approach to clinical tumor growth.Cancer1961;14:1272-94

[2] Yang JD.Hepatocellular carcinoma: a global view.Nat Rev Gastroenterol Hepatol2010;7:448-58 PMCID:PMC3926946

[3] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[4] Younossi ZM,Henry L.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology2015;62:1723-30

[5] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[6] Benhammou JN,Shirvanian G,Hussain SK.Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.Sci Rep2020;10:9902 PMCID:PMC7303220

[7] Kanwal F,Li L.Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease.Hepatology2020;71:808-19

[8] Barbara L,Gaiani S.Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival.Hepatology1992;16:132-7

[9] Sheu JC,Chen DS.Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.Gastroenterology1985;89:259-66

[10] Ebara M,Fukuda H.Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients.Hepatogastroenterology1998;45 Suppl 3:1214-20

[11] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[12] van Meer S,Coenraad MJ.Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands.J Hepatol2015;63:1156-63

[13] Rich NE,Parikh ND.Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multicenter cohort of patients with cirrhosis.Hepatology2020;72:1654-65 PMCID:PMC7398837

[14] Tong MJ,Huynh CT,Lu DS.Tumor growth rates and recurrence-free survival in chronic viral hepatitis patients with hepatocellular carcinoma Hepatoma Res 2019;5:36.

[15] Brunt EM.Histopathology of nonalcoholic fatty liver disease.World J Gastroenterol2010;16:5286-96 PMCID:PMC2980677

[16] Tong MJ,Huynh CT,Lu DSK.Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma.Hepatol Commun2017;1:595-608 PMCID:PMC5721434

[17] Kim TK,Jang HJ.Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.Radiology2011;259:730-8

[18] Lemon SC,Clark MA,Rakowski W.Classification and regression tree analysis in public health: methodological review and comparison with logistic regression.Ann Behav Med2003;26:172-81

[19] Friedman PJ.Classification of leiomyomatous lung lesions.AJR Am J Roentgenol1984;142:851-2

[20] Grohmann M,Dodd GT.Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC.Cell2018;175:1289-306.e20 PMCID:PMC6242467

[21] Huang DQ,Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2021;18:223-38 PMCID:PMC8016738

[22] Noureddin M,Alkhouri N,Dieterich DT.NASHNETscreening for nonalcoholic fatty liver disease in persons with Type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis.Gastroenterology2020;159:1985-7.e4

[23] An C,Choi D.Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease.Clin Mol Hepatol2015;21:279-86 PMCID:PMC4612289

[24] Nathani P,Rich N.Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.Gut2021;70:401-7 PMCID:PMC7657990

[25] Ioannou GN,Green PK.Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores.Gastroenterology2019;157:1264-78.e4 PMCID:PMC6815714

[26] Benhammou JN,Pisegna JR.Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C.Dig Dis Sci2021;66:2394-406 PMCID:PMC7854862

[27] Mehta N,Harnois DM.Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant.JAMA Oncol2017;3:493-500 PMCID:PMC5395317

[28] Nault JC.Biomarkers for hepatobiliary cancers.Hepatology2021;73 Suppl 1:115-27

[29] Parikh ND.Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma.Clin Liver Dis (Hoboken)2016;7:97-100 PMCID:PMC6490268

[30] Mehta N,Lee D.Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time "sweet spot".Transplantation2017;101:2071-8 PMCID:PMC5568965

[31] Goldberg DS,Serper M.Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.Hepatology2017;65:864-74

[32] Aby ES,Lin J.A telephone and mail outreach program successfully increases uptake of hepatocellular carcinoma surveillance.Hepatol Commun2020;4:825-33 PMCID:PMC7262281

[33] Simon TG,Aleman S.Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide swedish population.Ann Intern Med2019;171:318-27 PMCID:PMC8246628

[34] Simon TG,Ludvigsson JF.Association between aspirin use and risk of hepatocellular carcinoma.JAMA Oncol2018;4:1683-90 PMCID:PMC6440745